1
|
Claude L, Martino F, Hermand P, Chahim B, Roger P, de Bourayne M, Garnier Y, Tressieres B, Colin Y, Le Van Kim C, Romana M, Baccini V. Platelet caspase-1 and Bruton tyrosine kinase activation in patients with COVID-19 is associated with disease severity and reversed in vitro by ibrutinib. Res Pract Thromb Haemost 2022; 6:e12811. [PMID: 36514346 PMCID: PMC9732813 DOI: 10.1002/rth2.12811] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 08/22/2022] [Accepted: 09/01/2022] [Indexed: 12/13/2022] Open
Abstract
Background Severity of coronavirus disease 2019 (COVID-19) is often associated with thrombotic complications and cytokine storm leading to intensive are unit (ICU) admission. Platelets are known to be responsible for abnormal hemostasis parameters (thrombocytopenia, raised D-dimers, and prolonged prothrombin time) in other viral infections through the activation of the nucleotide-binding domain leucine repeat rich containing protein 3 inflammasome induced by signaling pathways driven by Bruton tyrosine kinase (BTK) and leading to caspase-1 activation. Objectives We hypothesized that caspase-1 activation and the phosphorylation of BTK could be associated with the severity of the disease and that ibrutinib, a BTK inhibitor, could inhibit platelet activation. Methods and Results We studied caspase-1 activation by flow cytometry and the phosphorylation of BTK by Western blot in a cohort of 51 Afro-Carribean patients with COVID-19 disease (19 not treated in ICU and 32 treated in ICU). Patients with a platelet count of 286.7 × 109/L (69-642 × 109/L) were treated by steroids and heparin preventive anticoagulation. Caspase-1 and BTK activation were associated with the severity of the disease and with the procoagulant state of the patients. Furthermore, we showed in vitro that the plasma of ICU patients with COVID-19 was able to increase CD62P expression and caspase-1 activity of healthy platelets and that ibrutinib could prevent it. Conclusions Our results show that caspase-1 and BTK activation are related to disease severity and suggest the therapeutic hope raised by ibrutinib in the treatment of COVID-19 by reducing the procoagulant state of the patients.
Collapse
Affiliation(s)
- Livia Claude
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Frédéric Martino
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Service de Réanimation, CHU de la GuadeloupePointe à PitreGuadeloupe
| | - Patricia Hermand
- Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Bassel Chahim
- Service Post‐Urgences, CHU de la GuadeloupePointe à PitreGuadeloupe
| | | | | | - Yohann Garnier
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Benoit Tressieres
- Centre d'Investigation Clinique Antilles Guyane, Inserm CIC 1424, CHU de la GuadeloupePointe‐à‐PitreGuadeloupe
| | - Yves Colin
- Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Caroline Le Van Kim
- Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Marc Romana
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Véronique Baccini
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance,Laboratoire d'HématologieCHU de la GuadeloupePointe à PitreGuadeloupe
| |
Collapse
|
2
|
Bernit E, Romana M, Alexis‐Fardini S, Tarer V, Roger P, Doumdo L, Petras E, Charneau C, Tressières B, Dessources MDH, Etienne‐Julan M. Sickle cell disease patients with COVID‐19 in Guadeloupe: Surprisingly favorable outcomes. eJHaem 2022; 3:636-643. [PMID: 35935270 PMCID: PMC9347453 DOI: 10.1002/jha2.449] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 03/29/2022] [Accepted: 04/08/2022] [Indexed: 11/09/2022]
Abstract
We investigate risk factors for hospitalization and difference between sickle cell syndromes in a cohort of COVID‐19 sickle cell disease (SCD) adult patients managed in the Reference Center of Guadeloupe. We retrospectively collected data of symptomatic SCD adult patients infected with SARS‐CoV‐2 between March and December 2020. Thirty‐eight SCD adult patients with symptomatic COVID‐19 infection were included during the first wave, representing 9.6% of the active patient file at our center. The median age (IQR) was 39 years (24–47). Four patients were obese and two had moderate renal failure. The median duration of symptoms (IQR) was 10 days (5–15). Seventeen (44.7%) patients were hospitalized, including two in intensive care unit (ICU) for acute chest syndrome. An 85‐year‐old SC patient with prostate cancer died. No difference was detected between inpatient and outpatient groups in terms of age, gender, BMI, SCD clinical complications, and in history SCD treatment. There was no difference for severity, hospitalization, length of stay, ICU stay, or death between SS or Sβ°‐thal patients and SC or Sβ+‐thal patients. These overall favorable outcomes among symptomatic patients may be related to the low prevalence of comorbidity known to be linked to the more severe forms of COVID‐19, but also to the prompt coordinated management of SCD patients in the Reference Center.
Collapse
Affiliation(s)
- Emmanuelle Bernit
- Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
| | - Marc Romana
- Laboratoire d'Excellence du Globule Rouge (Labex GR‐Ex) PRES Sorbonne Paris France
- Université des Antilles UMR_S1134/Inserm BIGR Pointe‐à‐Pitre Guadeloupe France
- Université de Paris UMR_S1134 BIGR INSERM Paris France
| | - Scylia Alexis‐Fardini
- Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
| | - Vanessa Tarer
- Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
| | - Pierre‐Marie Roger
- Service d'infectiologie CHU de la Guadeloupe Pointe à Pitre Guadeloupe France
| | - Lydia Doumdo
- Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
| | - Eléonore Petras
- Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
| | - Corine Charneau
- Sickle Cell Disease Unit Centre Hospitalier de la Basse‐Terre Basse‐Terre France
| | - Benoit Tressières
- Centre d'Investigation Clinique Antilles Guyane Inserm CIC Point‐à‐Pitre Guadeloupe France
| | - Marie Dominique Hardy Dessources
- Laboratoire d'Excellence du Globule Rouge (Labex GR‐Ex) PRES Sorbonne Paris France
- Université des Antilles UMR_S1134/Inserm BIGR Pointe‐à‐Pitre Guadeloupe France
- Université de Paris UMR_S1134 BIGR INSERM Paris France
| | - Maryse Etienne‐Julan
- Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
- Laboratoire d'Excellence du Globule Rouge (Labex GR‐Ex) PRES Sorbonne Paris France
- Université des Antilles UMR_S1134/Inserm BIGR Pointe‐à‐Pitre Guadeloupe France
- Université de Paris UMR_S1134 BIGR INSERM Paris France
| |
Collapse
|
3
|
Robin C, Broner J, Holubar J, Bergeret B, Roger P, Arnaud E, Goulabchand R. Efficacité du Belimumab sur une atteinte cutanée sévère de connectivite mixte. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Wandoren W, Roger P, Blanchet P, Brureau L. Étude préliminaire sur la conduite a tenir face à un ECBU polymicrobien en préopératoire d’une intervention urologique. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Manni S, Le Marechal M, Pugliese P, Etienne C, Prouvost-Keller B, Roger P, Cua E. PrEP en vie réelle : caractéristiques épidémiologiques des patients en prévention pré-exposition au VIH et incidence des infections sexuellement transmissibles notamment chez les personnes recrutées via une application de rencontre. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Souhail B, Challut N, Montera E, Tournoud S, Roger P, Gimel P. Complications infectieuses après pose de sonde JJ pour colique néphrétique : étude de cohorte prospective multicentrique. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Gregoire R, Bertrand B, Retur N, Collomp R, Mondain V, Roger P, Lieutier-Colas F. Audit régional sur les missions et outils des pharmaciens dans le Bon Usage des antibiotiques : des indicateurs nationaux à la « vraie vie ». Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
8
|
Michelangeli C, Girard-lamoulère D, Assi A, Della Guardia M, Roger P. Utilisation combinée des protocoles d’antibiothérapies et des antibiogrammes ciblés pour le bon usage des antibiotiques. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Roger P. The UK's legal position on Animal Sentience. Equine Vet J 2018; 50:277. [DOI: 10.1111/evj.12800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- P. Roger
- Veterinary Consultancy Services Richmond North Yorkshire UK
| |
Collapse
|
10
|
Raspé E, Coulonval K, Pita J, Paternot S, Rothé F, Twijffels L, Van Laere S, Ignatiadis M, Sotiriou C, Roger P. CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx138.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer 2017; 76:68-75. [PMID: 28284171 DOI: 10.1016/j.ejca.2017.02.003] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Revised: 01/21/2017] [Accepted: 02/01/2017] [Indexed: 01/15/2023]
Abstract
BACKGROUND Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy. PATIENTS AND METHODS We collected and analysed 143 samples of human colorectal tumours with complete clinical annotations, including the response to treatment. Gene expression profiling was used to classify patients in three to six classes using four different molecular classifications. Correlations between molecular subtypes, response to treatment, progression-free and overall survival were analysed. RESULTS We first demonstrated that the four previously described molecular classifications of colorectal cancer defined in non-metastatic patients also correctly classify stage IV patients. One of the classifications is strongly associated with response to FOLFIRI (P=0.003), but not to FOLFOX (P=0.911) and FOLFIRI + Bevacizumab (P=0.190). In particular, we identify a molecular subtype representing 28% of the patients that shows an exceptionally high response rate to FOLFIRI (87.5%). These patients have a two-fold longer overall survival (40.1 months) when treated with FOLFIRI, as first-line regimen, instead of FOLFOX (18.6 months). CONCLUSIONS Our results demonstrate the interest of molecular classifications to develop tailored therapies for patients with metastatic colorectal cancer and a strong impact of the first-line regimen on the overall survival of some patients. This however remains to be confirmed in a large prospective clinical trial.
Collapse
Affiliation(s)
- M Del Rio
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
| | - C Mollevi
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
| | - F Bibeau
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
| | - N Vie
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
| | - J Selves
- Centre Hospitalier Universitaire de Toulouse, F-31300, France; Centre de Recherche en Cancérologie de Toulouse, Unité Mixte de Recherche 1037 INSERM - Université Toulouse III, France
| | - J-F Emile
- Université de Versailles, Boulogne, France; Hôpital Ambroise Paré, Boulogne, France
| | - P Roger
- Université de Montpellier, Montpellier, F-34090, France; Service d'Anatomie et Cytologie Pathologiques, CHU Nîmes, Place du Professeur Debré, 30029, Nîmes, France
| | - C Gongora
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
| | - J Robert
- INSERM U916, Institut Bergonié, Université de Bordeaux, France
| | - N Tubiana-Mathieu
- Service d'oncologie médicale, CHU Dupuytren, avenue Luther-King, 87000, Limoges, France
| | - M Ychou
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France
| | - P Martineau
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34090, France; Institut régional du Cancer de Montpellier, Montpellier, F-34298, France.
| |
Collapse
|
12
|
Roger P, Leroux E, Roghi J, Dellaguardia M, Boivin H, Girard D. BU-05 - Infectiologue référent pour des établissements de soins privés : importance des infections associées aux soins. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30329-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Naqvi A, Joulie A, Perbost I, Prouvost-Keller B, Durant J, Pugliese P, Roger P, Rosenthal E. HEP-07 - Traitement de l’infection VHC par agents antiviraux directs chez 170 patients co-infectés par le VIH en 2014–2015 et description des patients à traiter en 2016. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30384-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Etien C, Mothes A, Dides P, Vassallo M, Roger P, Puglièse P. VAC-06 - Amélioration de la couverture vaccinale anti-pneumococcique d’une cohorte de patients vivants avec le VIH. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30532-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Aillet C, Demonchy E, Courjon J, Caisoo C, Roger P. PADS 1-10 - Influence d’une antibiothérapie préalable à l’hospitalisation chez les sujets âgés présentant une pneumonie aiguë communautaire sévère (PACs). Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30481-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Chirio D, Demonchy E, Martis N, Moceri P, Mothes A, Foucault C, De la Chapelle A, Chaillou S, Pietri P, Roger P. ENDO-08 - Endocardites infectieuses : audit régional sur la qualité de prise en charge. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30377-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Mollevi C, Del Rio M, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana N, Ychou M, Martineau P. Association entre les sous-types moléculaires et la réponse aux chimiothérapies dans le cancer colorectal métastatique. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.03.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
18
|
Vandenbos F, Roger P. Diminution de la durée de l’antibiothérapie dans les exacerbations aiguës de la BPCO. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Chirio D, Demonchy E, Cua E, Leroy S, Litrico S, Roger P. Un germe exceptionnel pour une complication classique d’une maladie rare. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Naqvi A, Dunais B, Garraffo R, Joulie A, De D, Puglièse P, Perbost I, Durant J, Roger P, Rosenthal E. Sofosbuvir/daclatasvir chez les patients co-infectés VIH/VHC avec une fibrose hépatique extensive : efficacité, tolérance et interactions pharmacologiques avec les antirétroviraux. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Chirio D, Demonchy E, Laffon M, Fournier-Mehouas M, Roger P, Ollier L, Piche T, Dellamonica P. Syndrome de Parsonage Turner et hépatite E : à propos de deux cas. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
22
|
Burns DT, Picard S, Kessler C, Roger P. Use of the BIPM calorimetric and ionometric standards in megavoltage photon beams to determineWairandIc. Phys Med Biol 2014; 59:1353-65. [DOI: 10.1088/0031-9155/59/6/1353] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
23
|
Souvannanorath S, Bouly S, Roger P, Renard D. Angiopathie amyloïde : une forme précoce et agressive. Rev Neurol (Paris) 2014; 170:46-8. [DOI: 10.1016/j.neurol.2013.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 03/19/2013] [Accepted: 03/21/2013] [Indexed: 10/26/2022]
|
24
|
Maenhaut C, Pirson I, Baptist M, Lamy F, Miot F, Roger P, Dumont JE. La cascade mitogène de l'AMPc dans la thyroïde et dans d'autres tissus. Med Sci (Paris) 2013. [DOI: 10.4267/10608/2187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
25
|
Rouanet P, Daures JP, Roger P, Mathieu A, Romieu G, Cretin J, Barneon G, Granier M, Maran-Gonzalez A, Thibault S, Boissiere F, Bibeau F. P2-12-16: HER2 Expression Is the Major Risk Factor for Recurrence in pT1a-b,N0 Breast Cancer: A French Regional Population-Based Study of 671 Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: To evaluate the prognostic impact of HER2 overexpression in patients with pT1a-b, node negative, breast cancers.
Patients and Methods: A population of1127 patients whose diseases were staged as pT 1a-b, pN0 and who were treated in the Languedoc-Roussillon (ONCO LR Southern French regional network) from 1999 to 2004, was identified. 95% of patients had conservative management, no patient received adjuvant trastuzumab, 5% received chemotherapy and 80% anti-estrogen endocrine therapy. HER 2 status was retrospectively assessed by immunohistochemistry in 671 patients (122 pT1a/549 pT1b). Kaplan-Meier method was used to estimate disease-free survival (DFS). Cox proportional hazard models were used to determine associations between HER2 status and disease-free survival adjusting on variables significantly linked to it.
Results: 9-year Overall survival was 95%. HER2 overexpression (3+) was observed in 5.2% of the patients (n=35).
HER2 3+ category was most frequently identified in the following sub groups: pT1a lesion (12.3% vs 3.6%; p: 0.0001), mastectomies (14% vs 4.4%; p:0.023), Grade 2–3 (91% vs 50%; p<0.0001), estrogen receptor (ER) negative (−) tumors (57% vs 30%; p<0.0001), progesterone receptor (PR) - tumors (74% vs 42%; p: 0.0002). HER2 3+ was less frequent with adjuvant hormonal treatment (43% vs 80%; p<0.0001). 33 relapse (5%) were observed with a median follow-up of 6.4 years (range, 0.3 to 9.9 years). The 5-year DFS rates were 78% and 95% in patients with HER2−positive and HER2−negative tumors, respectively (p:0.017).
According to the immunohistochemical phenotype DFS5 were 95%, 94%, 85%, 73.6% for ER+/PR+/HER2− (n:502/75%), ER-/PR-/ HER2− (n:134/20%), ER+/PR+/HER2 3+ (n:15/2%) and ER-/PR-/ HER2 3+ tumors (n:20/3%), respectively (p:0.02).
In univariate analysis, HER2 positive tumors (p:0.017), phenotype classification (p:0.02) and adjuvant treatment (p:0.013) were significant prognostic factors. In multivariate analysis, only patients with HER2 3+ tumors had higher risks of recurrence (hazard ratio [HR], 2.41; 95% CI: [1.06−5.53]; p<0.05) than those with HER2 -tumors.
Discussion: Node-negative, pT1a-b, breast cancer patients overexpressing HER2 have a significant risk of recurrence at 6 years median follow-up. In our series of small breast tumors, HER2 status seems to be a better prognostic factor than ER status. In patients with hormone receptor-positive diseases, HER2 positivity is associated with a worse DFS despite an anti-estrogen treatment.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-16.
Collapse
Affiliation(s)
- P Rouanet
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - JP Daures
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - P Roger
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - A Mathieu
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - G Romieu
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - J Cretin
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - G Barneon
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - M Granier
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - A Maran-Gonzalez
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - S Thibault
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - F Boissiere
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| | - F Bibeau
- 1Val d'Aurelle Cancer Institute, Montpellier, France; Montpellier 1 University, Montpellier, France; CHU Nimes, Nimes, France; ONCO LR Regional Network, Montpellier, France
| |
Collapse
|
26
|
Abstract
AIMS To help gain a better understanding of factors influencing the establishment within the oral cavity of Streptococcus salivarius K12, a commensal oral bacterium, we characterized its behaviour in artificial saliva. METHODS AND RESULTS Streptococcus salivarius K12 was grown in artificial saliva complemented with a representative meal, under oral pH and temperature conditions. Exponential growth phase was characterized by a high specific growth rate (2.8 h(-1)). During maintenance phase, an uncoupling between growth and lactic acid production occurred, which allowed maintaining viability (95%), intracellular pH (6.6) and membrane polarisation (95%), and thus proton motive force. However, in late stationary phase, viability (64%) and vitality were degraded as a result of lower synthesis of energetic and glycogen-related proteins as compared to a richer medium. CONCLUSIONS Streptococcus salivarius was able to rapidly grow in complemented artificial saliva. Nevertheless, a degradation of its physiological state was observed in late-stationary phase. SIGNIFICANCE AND IMPACT OF THE STUDY This work demonstrates, for the first time, that artificial saliva was a convenient medium that permitted Strep. salivarius to grow in oral conditions (physico-chemical environment, addition of meals) but not to maintain cellular viability and vitality in starvation conditions.
Collapse
Affiliation(s)
- P Roger
- AgroParisTech, INRA, UMR782, Thiverval-Grignon, France
| | | | | | | |
Collapse
|
27
|
Henry L, Le Gallic L, Garcin G, Coux O, Jumez N, Roger P, Lavabre-Bertrand T, Martinez J, Meunier L, Stoebner P. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin. Br J Dermatol 2011; 165:311-20. [DOI: 10.1111/j.1365-2133.2011.10447.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Arnould L, Roger P, MacGrogan G, Lannes B, Hayem C, Campana F, Balaton A, Penault-Llorca F. HER2 status determined on pre operative biopsies and in operative specimens: concordance among immunohistochemistry (IHC) fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) techniques in the CRITHER study. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1089
Background: In breast cancer, HER2 status is generally assessed by IHC or FISH on operative tissue sample and in situ hybridization techniques are standard tools for determining equivocal IHC 2+ overexpression and deciding the correct treatment for HER2-positive breast cancer patients. For the management of their patients, oncologists or surgeons sometimes ask for assessment of HER2 status on per cutaneous core biopsy (CB).The primary objective of the CRITHER study was to investigate concordance between the results of CISH, FISH, and IHC techniques on pre-operative CB samples for HER2 status compared with HER2 status determined by FISH on surgical specimen from a population of previously untreated non-metastatic breast cancer patients in France. Methods: Analysis was performed on samples from 260 patients recruited at 24 pathology centers for the period 2003 to 2006 inclusive. Recruitment was made on the basis of IHC obtained from operative tissue samples in order to obtain around 50% HER2-positive (3+), 30% HER2-negative (0/1+), and 20% HER2-equivocal (2+) cases. CISH and IHC were performed in parallel on the pre-operative biopsy and matched surgical specimen in the participating laboratories, and FISH on both specimens in each of four reference pathology centers. IHC staining was analyzed according to different scoring systems. Results: The rate of discordance between pre-operative CISH and operative FISH was 1.8% with 1.5% false-positives and 2.2% false-negatives (k=0.963; p<0.001); the corresponding rate for pre-operative IHC (excluding equivocal IHC 2+ cases) and operative FISH was 1.5% with 1.6% false-positives and 1.4% false-negatives (k=0.953; p<0.001). Comparison of pre-operative and operative samples showed expected low rates of discordance for CISH (0.85%; k=0.982; p<0.001) and FISH (0.45%; k=0.991; p<0.001), with no false positives in either case. Results for the IHC scoring system analyses on concordance will be presented at the meeting. Discussion: As expected, concordance for both CISH and FISH between pre-operative and operative results was excellent. There was a high rate of concordance for pre-operative CISH and IHC HER2 status determination on CB (excluding equivocal IHC 2+ cases) compared with operative FISH results in patients with previously untreated non-metastatic breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1089.
Collapse
Affiliation(s)
- L Arnould
- 1 Department of Pathology, Centre G-F Leclerc, Dijon, France
| | - P Roger
- 2 Department of Pathology, Hôpital Lapeyronie, CHU Montpellier, Montpellier, France
| | - G MacGrogan
- 3 Department of Pathology, Institut Bergonie, Bordeaux, France
| | - B Lannes
- 4 Departement de Pathologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
| | - C Hayem
- 5 Roche, Neuilly-sur-Seine, France
| | | | - A Balaton
- 6 Department of Pathology, Centre de Pathologie, Bievres, France
| | - F Penault-Llorca
- 7 Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France
| |
Collapse
|
29
|
Stoebner P, Fabre C, Delfour C, Joujoux J, Roger P, Dandurand M, Meunier L. Solitary Subungual Keratoacanthoma Arising in an MSH2 Germline Mutation Carrier: Confirmation of a Relationship by Immunohistochemical Analysis. Dermatology 2009; 219:174-8. [DOI: 10.1159/000228830] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2009] [Accepted: 03/31/2009] [Indexed: 11/19/2022] Open
|
30
|
Taourel P, Hoa D, Chaveron C, Balu-Maestro C, Gros D, Baranzelli MC, Ettore F, Bretz-Grenier MF, Roger P. Stereotactic vacuum biopsy of calcifications with a handheld portable biopsy system: a validation study. Eur Radiol 2008; 18:1319-25. [PMID: 18351352 DOI: 10.1007/s00330-008-0897-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2007] [Revised: 01/29/2008] [Accepted: 02/04/2008] [Indexed: 11/30/2022]
Abstract
To prospectively evaluate a compact portable 10-gauge handheld battery-operated biopsy system for stereotactic biopsy of microcalcifications. The ethics committee of the hospital approved this prospective multicentric study, and informed consent was obtained. Biopsy under stereotactic guidance was performed in 215 patients for 219 lesions consisting of microcalcifications without mass. The feasibility and the tolerance of the procedure were evaluated. The mean weight of the specimen was calculated. In patients with surgical diagnoses, the underestimation rate in biopsy diagnoses of atypical ductal hyperplasia and ductal carcinoma in situ were evaluated. The sampled specimens were separated according to the presence of calcifications on magnified specimen radiographs and to the probe the rotation number in order to evaluate the contribution of each rotation and the contribution of the specimen with and without calcifications on the radiographs. The macrobiopsy was feasible in 98.5% of the patients and was well tolerated in 82% of patients. It identified 4.6% invasive carcinomas, 18.5% ductal carcinomas in situ, 14.8% atypical ductal hyperplasias, 22.2% benign proliferative mastopathies and 39.8% benign non-proliferative mastopathies. The underestimation rate was 26.6% when an atypical ductal hyperplasia was diagnosed at biopsy, and 7.7% when a ductal carcinoma in situ was diagnosed. In the 77 patients with surgical correlation, the accurate diagnosis was obtained in specimens sampled during the first, second, and third in 69%, 9%, and 4% of the biopsies, respectively, and the analysis of specimens without microcalcification had an added value in 8% of patients. The compact portable battery-operated biopsy system can be used successfully for stereotactic biopsy of microcalcifications and constitutes a valid alternative to current systems.
Collapse
Affiliation(s)
- P Taourel
- Department of Radiology, CHU Montpellier, Montpellier, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Pfammatter T, Amann-Vesti B, Lachat M, Roger P. Abstract No. 47: Preclosing of Antegrade Femoral Access for Large Bore Suction Thrombectomy Is Safe. J Vasc Interv Radiol 2008. [DOI: 10.1016/j.jvir.2007.12.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
32
|
|
33
|
Giacalone PL, Dubon O, Roger P, El Gareh N, Rihaoui S, Daurés JP. Doughnut mastopexy lumpectomy versus standard lumpectomy in breast cancer surgery: A prospective study. Eur J Surg Oncol 2007; 33:301-6. [PMID: 17110076 DOI: 10.1016/j.ejso.2006.09.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2006] [Accepted: 09/15/2006] [Indexed: 10/23/2022] Open
Abstract
AIMS Doughnut mastopexy lumpectomy (DML) is a unique breast resection in which a tissue segment is removed and the breast reshaped through a periareolar incision. The present prospective investigation compares DML and standard lumpectomy (SL) in relation to surgical variables, histological parameters, postoperative morbidity and cosmetic outcome. METHODS 127 patients with breast cancer were offered the choice between two conservative surgical approaches: doughnut mastopexy lumpectomy (DML group, n=39) or standard lumpectomy (SL group, n=88). The groups were comparable for radiological tumour size, tumour location within the breast, histological size, and pT category. Comparison was performed in term of surgical variables, histological parameters, postoperative morbidity and cosmetic outcome. RESULTS The patients undergoing DML were younger than the patients who chose SL. In the DML group, the skin incision was 3-fold longer than in the SL group but was obtained with a final scar located around the nipple areola complex without further postoperative complications. The average volume of the breast specimen was higher in the DML group compared with SL group. The clinician assessment of cosmetic outcome reported a higher rate of acceptable result in the DML group than in the SL group. However, patient's assessment did not show difference of cosmetic satisfaction between groups. CONCLUSION Our comparative study indicates that DML may be a useful alternative to SL not only in terms of accurate breast tissue resection but also in term of cosmetic results.
Collapse
Affiliation(s)
- P L Giacalone
- Oncology Unit, Department of Obstetrics and Gynecology, Hôpital Arnaud de Villeneuve, 371 rue du Doyen Gaston Giraud, Herault, 34295 Montpellier Cedex 5, France.
| | | | | | | | | | | |
Collapse
|
34
|
Ujang Z, Ng KS, Tg Hamzah TH, Roger P, Ismail MR, Shahabudin SM, Abdul Hamid MH. Application of immersed MF (IMF) followed by reverse osmosis (RO) membrane for wastewater reclamation: A case study in Malaysia. Water Sci Technol 2007; 56:103-108. [PMID: 18025737 DOI: 10.2166/wst.2007.700] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
A pilot scale membrane plant was constructed and monitored in Shah Alam, Malaysia for municipal wastewater reclamation for industrial application purposes. The aim of this study was to verify its suitability under the local conditions and environmental constraints for secondary wastewater reclamation. Immersed-type crossflow microfiltration (IMF) was selected as the pretreatment step before reverse osmosis filtration. Secondary wastewater after chlorine contact tank was selected as feed water. The results indicated that the membrane system is capable of producing a filtrate meeting the requirements of both WHO drinking water standards and Malaysian Effluent Standard A. With the application of an automatic backwash process, IMF performed well in hydraulic performance with low fouling rate being achieved. The investigations showed also that chemical cleaning is still needed because of some irreversible fouling by microorganisms always remains. RO treatment with IMF pretreatment process was significantly applicable for wastewater reuse purposes and promised good hydraulic performance.
Collapse
Affiliation(s)
- Z Ujang
- Institute of Environmental and Water Resource Management, Faculty of Civil Engineering, Universiti Teknologi Malaysia, Johor, Malaysia.
| | | | | | | | | | | | | |
Collapse
|
35
|
Caouthar A, Roger P, Tessier M, Chatti S, Blais J, Bortolussi M. Synthesis and characterization of new polyamides derived from di(4-cyanophenyl)isosorbide. Eur Polym J 2007. [DOI: 10.1016/j.eurpolymj.2006.08.012] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Marshall M, Roger P. Policy and science of FMD control: the stakeholders' contribution to decision making. A call for integrated animal disease management. J Clin Lab Immunol 2006; 53:27-38. [PMID: 16805323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Effective control of foot-and-mouth disease (FMD)--prevention, surveillance and response--requires integrated animal disease management as a cooperative effort between stakeholders, scientists and decision makers, at all levels: local, national, regional and international. This paper suggests a process and outlines specific critical issues that need to be addressed in order to best use the science and technology that is available now and to develop new technologies that will lead to significant improvements. The overall objective is not to allow the disease or the disease control measures to damage, violate or destroy public health, the environment, or the economy, or to allow politics to drive disease control policies at the expense of the ethical relationship between man and animals. Critical issues of prevention, surveillance and response policies are examined, and specific recommendations are made to reduce the risk or effect of natural and deliberate introductions. For prevention: a) rapid portable diagnostics and provision of vaccines to control and eradicate the reservoirs of disease. b) alerts, leading to increased controls at borders, animal movement restrictions and biosecurity on farms. For surveillance: a) reporting of unusual symptoms, rapid diagnostics and identification of patterns. b) enhanced role of geographic information systems (GIS) linked to an IT system. c) collection, storage and sharing of disease information. For response policies: a) the role and implementation of stamping out and of vaccination. b) simulation exercises with stakeholder participation. For all aspects of FMD control, consideration should be given to: a) the composition, responsibilities and role of the balanced, permanently operational Expert Group in EU member states as specified in the EU FMD Directive. b) establishment of a balanced, permanently operational European Expert Group. c) establishment of both a European and an International FMD Task Force. Stakeholders need access to accurate, up-to-date, unbiased information about the science of disease control, how the technologies work and can be used, and an assurance that the technologies best fit for the required purpose will be used. Researchers need to work together to avoid duplications and gaps in their research and to recognise the benefit of new, and sometimes innovative, technologies. They also need feedback from stakeholders on the acceptability and best use of the technologies. A process to achieve these goals through an EU funded collaborative research project will be described.
Collapse
Affiliation(s)
- M Marshall
- Animal Health Resources Ltd, Summertown, Oxford, UK.
| | | |
Collapse
|
37
|
Sion R, Schumer A, Van Durme E, Gouyette A, Geslin M, Fournier JP, Berger Y, Roger P. Synthese du methyl [(chloro-2 ethyl)-3 nitroso-3 ureido]-3 didesoxy-2, 3 α-D-arabino-hexopyrannoside marque AU carbone-14 OU −AU carbone-13 (CY 233 - SR 90098). J Labelled Comp Radiopharm 2006. [DOI: 10.1002/jlcr.2580280605] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
38
|
Giacalone PL, Roger P, Dubon O, El Gareh N, Daurés JP, Laffargue F. Traitement conservateur des cancers du sein : zonectomie vs oncoplastie. Étude prospective à propos de 99 patientes. ACTA ACUST UNITED AC 2006; 131:256-61. [PMID: 16530156 DOI: 10.1016/j.anchir.2005.12.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2005] [Accepted: 12/20/2005] [Indexed: 11/29/2022]
Abstract
UNLABELLED The integration of oncoplastic techniques with a concomitant contralateral symmetrization procedure is a novel surgical approach that allows wide excisions and prevents breast deformities. AIM OF THE STUDY This prospective study was undertaken to compare the accuracy of breast resection, between standard narrow lumpectomy and oncoplastic surgery. PATIENTS AND METHODS Ninety-nine consecutive women undergoing breast cancer resection were enrolled in a prospective study comparing oncoplastic surgery (42 women) and standard lumpectomy (57 women). The size of the glandular resection, the width of the nearest margins, the ratio of clear margins and the need for further surgery were recorded. RESULTS The oncoplastic approach resulted in significantly greater glandular resection and wider free histological margins than did standard lumpectomy. The need for re-exicsional surgery was significantly lower in the oncoplastic group than in the lumpectomy group. Furthermore, a trend towards fewer secondary mastectomies was seen for the oncoplastic approach versus standard lumpectomy. CONCLUSIONS The use of oncoplastic techniques and concomitant symmetrization of the contralateral breast allows extensive resections for conservative treatment of breast carcinoma achieves accurate tumour resection and reduces the need for further surgery.
Collapse
Affiliation(s)
- P-L Giacalone
- Service de Gynécologie-Obstétrique, Unité de Chirurgie Oncologique et Mammaire, Hôpital Arnaud-de-Villeneuve, Montpellier, France.
| | | | | | | | | | | |
Collapse
|
39
|
Roger P. [Breast macrobiopsy: the need for standardized terminology]. ACTA ACUST UNITED AC 2006; 87:263-4. [PMID: 16550109 DOI: 10.1016/s0221-0363(06)73999-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Rouleau C, Serre I, Roger P, Guibal MP, Galifer RB, Bonardet A, Baldet P. Acinar cell carcinoma of the pancreas in a young patient with cells immunoreactive for somatostatin. Histopathology 2006; 48:307-9. [PMID: 16430479 DOI: 10.1111/j.1365-2559.2005.02216.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Abstract
Breast carcinomas with false negative mammogram correspond to carcinomas diagnosed with means other than mammogram when the mammogram, at the time of diagnosis, showed no significant abnormality. The rate of false mammogram is difficult to ascertain because few studies have been published on this subject. The absence of mammographic abnormality is related to histopathological characteristics of the tumor and mammographic features of the patient's breast tissue. The small size of the tumor, the lack of microcalcifications often due to tumor necrosis and the absence of any significant associated desmoplastic reaction are the main histopathological factors encountered, particularly for dense breasts.
Collapse
Affiliation(s)
- P Roger
- Service d'Anatomie Pathologique, CHU de Montpellier. 34295 Montpellier Cedex 5
| | | | | | | | | | | |
Collapse
|
42
|
|
43
|
Roger P, Ragu N, Bibeau F, Delfour C, Serre I, Baldet P, Taourel P. Caractéristiques histopathologiques des carcinomes mammaires sans signes mammographiques – étude rétrospective portant sur 15 patientes. Ann Pathol 2004. [DOI: 10.1016/s0242-6498(04)94145-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Giacalone PL, Deisseignet PH, Roger P, Taourel P, Vernet H, Laffargue F. Pre-operative arterial embolisation of a uterine rhabdomyosarcoma in a 14-year-old girl. Br J Radiol 2004; 77:701-3. [PMID: 15326055 DOI: 10.1259/bjr/31755088] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
We report a young patient suffering from a uterine rhabdomyosarcoma. Particular features of the present case are: accuracy of the tumour spread evaluation performed by MRI of the pelvis; and the use of pre-operative arterial embolisation. The present multimodal management highlights the usefulness of cooperation between surgeons and radiologists in lowering operative bleeding and finally permitting uterine conservation.
Collapse
Affiliation(s)
- P L Giacalone
- Oncology Unit, Department of Obstetrics and Gynaecology, Hôpital Arnaud de Villeneuve, 371 rue du Doyen Gaston Giraud, 34295 Montpellier, France
| | | | | | | | | | | |
Collapse
|
45
|
Boulet P, Roger P, Giacalone P. Cas-radio-clinique — discussion interactive. Imagerie de la Femme 2004. [DOI: 10.1016/s1776-9817(04)94804-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
Roger P. [New regulation mechanisms of cell cycle shown by analysis of thyroid cell proliferation stimulated by TSH and cyclic AMP]. Bull Mem Acad R Med Belg 2004; 159:396-405. [PMID: 15693550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
In thyroid gland, different tumor types are associated with the oncogenic activation of distinct mitogenic cascades, which are normally activated either by TSH via cAMP or by growth factors. In primary cultures of thyroid cells, the cAMP-dependent mitogenic pathway, which is associated with an increased differentiation expression, does not involve most of the intermediates of the classical signalling pathways of growth factors. Especially, we have shown that TSH and cAMP trigger and support cell cycle progression, but they do not upregulate D-type cyclins and they paradoxically increase the accumulation of the CDK inhibitor p27kip1. Instead, cAMP phosphorylates and inactivates pRb by inducing the assembly and nuclear translocation of the cyclin D3-CDK4-p27 holoenzyme, and then by stimulating the activating phosphorylation of CDK4 within this complex.
Collapse
Affiliation(s)
- P Roger
- Institut de Recherches Interdisciplinaires en Biologie Humaine et Moléculaire, Campus Erasme, Faculté de Médecine, ULB
| |
Collapse
|
47
|
Denoux Y, Arnould L, Fiche M, Lannes B, Couturier J, Vincent-Salomon A, Penault-Llorca F, Antoine M, Balaton A, Baranzelli MC, Becette V, Bellocq JP, Bibeau F, Ettore F, Fridman V, Gnassia JP, Jacquemier J, MacGrogan G, Mathieu MC, Migeon C, Rigaud C, Roger P, Sigal-Zafrani B, Simony-Lafontaine J, Trassard M, Treilleux I, Verriele V, Voigt JJ. [HER2 gene amplification assay: is CISH an alternative to FISH?]. Ann Pathol 2003; 23:617-22. [PMID: 15094603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The HER2 proto-oncogene encodes a transmembrane protein, which is considered to function as a growth factor receptor. Overexpression of this protein found by immunohistochemistry in about 20% of infiltrating breast carcinomas, has a predictive value of response to treatment by trastuzumab, an anti-HER2 humanized monoclonal antibody. Search for HER2 gene amplification is necessary to adapt the immunohistochemical technique quality and also in the cases of delicate analysis or weak overexpression. It is usually carried out by Fluorescence In Situ Hybridization (FISH). A more recent hybridization technique, named CISH because of its chromogenic revelation is an alternative method, which gives highly correlated results with FISH. We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining.
Collapse
Affiliation(s)
- Yves Denoux
- Service d'Anatomie Pathologique, Centre François Baclesse, 14076 Caen cedex 5.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Jaquet P, Cortet-Rudelli C, Sassolas G, Morange-Ramos I, Chanson P, Brue T, Andrieu JM, Beckers A, Bertherat J, Borson-Chazot F, Brassier G, Caron P, Cogne M, Cottier JP, Delemer B, Dufour H, Enjalbert A, Figarella-Branger D, Gaillard R, Gueydan M, Jan M, Kuhn JM, Raingeard I, Regis J, Roger P, Rohmer V, Sadoul JL, Saveanu A, Tabarin A, Travers N, Trouillas J. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry]. Ann Endocrinol (Paris) 2003; 64:434-41. [PMID: 15067248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
UNLABELLED From the first 198 patient files included into the French Acromegaly Registry, we analyzed 68 patients harboring a somatotroph adenoma with extrasellar extension, after exclusion of those treated by stereotactic or conventional radiotherapy. In these patients (including 37 women), aged 21-77 yr. (45.7 +/- 13.3), GH concentrations ranged from 2-260 microg/L (38.6 +/- 44.3), and IGF I from 86-967% of age-matched upper limit of normal (303 +/- 164). Maximal diameter of the adenoma at MRI was 11-36.5 mm (20.4 +/- 6.5), with cavernous sinus involvement in 68% of cases. Three subgroups were defined: 20 patients treated by long-acting somatostatin analogs only (group M), for a mean duration of 3 yr. (extremes 1-7 yr.), 48 patients initially treated by transsphenoidal surgery (group C), of whom 21 were secondarily treated by long-acting somatostatin analogs (group CM) for a mean duration of 1.2 yr. (extremes 0.2-2 yr.). All 3 groups were not statistically different in terms of tumor mass and initial levels of GH and IGF-1. Patients from group M were significantly older than those of the other groups (p<0.05). RESULTS 46% of patients from group C after surgery vs. 45% of patients from group M had a mean GH below 2.5 microg/L. Biochemical remission (GH<2.5 microg/L and normal IGF1 normal) was obtained in 31% of cases in group C, vs. 25% in group M. In this group, a decrease of the largest tumor diameter was observed in 10 patients (71.5%), ranging from 10-25% in 7 (50%) and exceeded 50% in 3 (21.5%). In group CM, the biochemical remission rate (42%) and final GH or IGF1 values were not significantly different from group M. In conclusion, these data suggest that surgery or long-acting somatostatin analogs have a comparable efficacy in terms of remission rates in somatotroph macroadenomas with extrasellar extensions.
Collapse
Affiliation(s)
- Ph Jaquet
- Service d'Endocrinologie, Diabète et Maladies métaboliques, Hôpital de la Timone, 264, rue Saint-Pierre, 13005 Marseille
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Chatti S, Bortolussi M, Loupy A, Blais JC, Bogdal D, Roger P. Synthesis of new polyethers derived from isoidide under phase-transfer catalysis: Reactivity and selectivity under microwaves and classical heating. J Appl Polym Sci 2003. [DOI: 10.1002/app.12719] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
50
|
Leplège A, Ecosse E, Archambau F, Arlot S, Bachelot I, Bercovici JP, Bouchard P, Colle M, Dewailly D, Hassler P, Lorcy Y, Luton JP, Roger P, Valensi P, Schaison G. [Pilot study and preliminary validation of the French version of a quality-of-life questionnaire specific for subjects with growth hormone deficiency]. Ann Endocrinol (Paris) 2003; 64:191-7. [PMID: 12910060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
This study forms part of a research project seeking to develop a standardized questionnaire by which clinicians can assess the impact of growth hormone (GH) deficiency and its treatment on the "perceived health" or health-related quality of life of adults. The specific aim of this study was to translate and adapt for French patients the AGHDA (Adult Growth Hormone Deficiency Assessment) a standardized health-related quality of life measure for use with GH-deficient adults, initially developed in the United Kingdom, and to collect data which could be used to assess the main psychometric characteristics of its French version the ISPA-HC (Indicateur de Santé Perceptuelle Adulte-Hormone de Croissance). The main properties analyzed are: 1/ The scale's acceptability, as determined by means of face-to-face interviews with a small number of subjects, then by an ad hoc questionnaire administered during a test-retest study; 2/ The scale's reliability, as determined by a test-retest study (with a 15-days interval between tests); 3/ The scale's concurrent validity, as expressed by comparison with scores obtained by means of a generic quality of life scale, the ISPN (the French version of the Nottingham Health Profile). The results of this first trial with the ISPA-HC are conforming to what one can expect from a good instrument. The ISPA-HC has been shown to have very good levels of reliability and internal consistency. Its scores show a close correlation with those of the ISPN (the French version of the Nottingham Health Profile). This instrument can be used to measure variations in the perceived health of subjects with growth hormone deficiency. Its responsiveness to change is to be examined in subsequent studies.
Collapse
Affiliation(s)
- A Leplège
- EA 2494, UFR Cochin-Port Royal, Université Paris V, 27 rue du Faubourg Saint Jacques, F-75014 Paris.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|